Hetran 20 Tablet contains Vonoprazan 20 mg, a potassium-competitive acid blocker (P-CAB) indicated for the treatment of acid-related gastrointestinal disorders. Vonoprazan exerts its therapeutic effect by selectively and reversibly inhibiting the H+/K+-ATPase enzyme in gastric parietal cells, leading to potent and sustained suppression of gastric acid secretion. This mechanism provides rapid onset of action and prolonged acid inhibition compared to traditional proton pump inhibitors (PPIs). Hetran 20 is primarily prescribed for the management of gastroesophageal reflux disease (GERD), including erosive esophagitis, peptic ulcers, and Helicobacter pylori eradication in combination with appropriate antibiotics. The tablet is administered orally, typically once daily, with or without food, as directed by a healthcare professional. Clinical studies have demonstrated that Vonoprazan offers improved healing rates and symptom relief in acid-related disorders, with a favorable safety and tolerability profile. Common adverse effects may include headache, diarrhea, and abdominal discomfort, though these are generally mild and transient. Hetran 20 should be used cautiously in patients with hepatic impairment and is contraindicated in individuals with known hypersensitivity to Vonoprazan or any tablet components. Regular monitoring and adherence to prescribed dosage are essential to optimize therapeutic outcomes and minimize potential risks.